<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Salk Institute on Medium]]></title>
        <description><![CDATA[Stories by Salk Institute on Medium]]></description>
        <link>https://medium.com/@salkinstitute?source=rss-25ad4702628b------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/0*TswvY1OWxuFHdFbJ.jpeg</url>
            <title>Stories by Salk Institute on Medium</title>
            <link>https://medium.com/@salkinstitute?source=rss-25ad4702628b------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Fri, 20 Nov 2026 18:05:11 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@salkinstitute/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[TAKING AIM AT FIVE DEADLY CANCERS]]></title>
            <link>https://medium.com/@salkinstitute/taking-aim-at-five-deadly-cancers-e597b537b80d?source=rss-25ad4702628b------2</link>
            <guid isPermaLink="false">https://medium.com/p/e597b537b80d</guid>
            <category><![CDATA[brain-cancer]]></category>
            <category><![CDATA[breast-cancer]]></category>
            <category><![CDATA[cancer]]></category>
            <category><![CDATA[pancreatic-cancer]]></category>
            <category><![CDATA[lung-cancer]]></category>
            <dc:creator><![CDATA[Salk Institute]]></dc:creator>
            <pubDate>Sat, 23 Jun 2018 14:49:50 GMT</pubDate>
            <atom:updated>2018-06-23T23:25:00.636Z</atom:updated>
            <content:encoded><![CDATA[<h4>Cancer is not like other diseases. Most conditions have external causes — bacteria, viruses, injury — but cancer comes from inside us. Cells go rogue, divide recklessly, invade other tissues and spread throughout the body. They do things normal cells cannot do.</h4><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*6kCgRe54Y72VMYRaAZZOFw.png" /></figure><p>The word itself evokes fear. Cancer is secretive, terrifying. It grows unobserved, recodes itself to escape treatment and co-opts normal biology to keep growing. To add complexity, cancer is not one disease but many — hundreds, perhaps thousands.</p><p>For these and other reasons, cancers are among the most difficult conditions to treat. Nearly 50 years after the United States declared a War on Cancer, it remains the second-leading killer after heart disease and causes untold suffering.</p><p>To change that, <a href="https://www.salk.edu/science/research-centers/salk-cancer-center/">Salk’s NCI-designated Cancer Center</a> — one of the first such centers in America — is launching the <a href="https://www.salk.edu/science/research-centers/salk-cancer-center/conquering-cancer-initiative/">Conquering Cancer Initiative</a>. This five-year, $55 million effort will bring together scientists in more than 30 Salk labs to harness new strategies against five deadly cancers: pancreatic, ovarian, lung, brain (glioblastoma) and triple-negative breast. Together, Salk researchers will identify cancer’s vulnerabilities and find new methods to attack tumors and leave healthy tissue alone.</p><p>“We have historical expertise with making discoveries in these five intractable cancers,” says Salk Cancer Center Director <a href="https://www.salk.edu/scientist/reuben-shaw/">Reuben Shaw</a>. “And because they are among the most complex and deadly, if we can make headway against them, we will make advances against many cancers.”</p><h3>Hitting back</h3><p><a href="https://www.salk.edu/science/research/cancer-biology/">Cancers</a> are genetic diseases, and they’re exceptionally patient. A tumor may start with a single mutation in a growth pathway, the genes that tell cells to grow and divide. This is a normal function — if you cut yourself, adjacent cells grow faster for a time and heal the wound. But these mutations can eliminate molecular “off” switches, allowing cells to continue multiplying.</p><p>By itself, such a variation might not be enough to generate a tumor. The body has excellent defenses, such as the immune system and DNA safeguards. For example, the p53 protein scans for genetic anomalies and shuts down cell division to correct them. If the mistakes can’t be fixed, p53 initiates the cell’s self-destruct mechanism, a function called apoptosis.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/880/1*iyg_X1zeoWDANhxnW5h3YQ.png" /></figure><p><a href="http://inside.salk.edu/wp-content/uploads/2018/05/big-five-spring-summer-hr.jpg">Click here for a high-resolution infographic.</a></p><p>These systems keep mutated cells at bay, but over time — years or even decades — they can fail. Cancer cells learn to fool the immune system into thinking they are normal tissue. Mutations corrupt p53 and other quality-control mechanisms.</p><p>Without these safeguards, random mutations appear more rapidly, and some confer survival advantages for tumors. Proteins that initiate apoptosis get shut down. Molecules that pump toxins, such as chemotherapy, out of cells get turned up. Some cancers become virtually invulnerable to current treatments. Eventually, the tumor invades surrounding tissue and spreads throughout the body, a process called metastasis.</p><p>But strengths can also be weaknesses. The same mutations that help tumors survive can be targeted for treatment. The key is learning how these cellular mechanisms work — something Salk scientists have excelled at for more than 50 years (see sidebar “Intellectual firepower”).</p><p>“The Salk Cancer Center aims to push back the boundaries of fundamental understanding of cancer and use that knowledge to develop new therapeutics,” says Shaw. “By being bold, by being innovative and by being collaborative, we hope to turn the tide against cancer.”</p><iframe src="https://cdn.embedly.com/widgets/media.html?src=https%3A%2F%2Fwww.youtube.com%2Fembed%2FkNMffxJ2f7E%3Ffeature%3Doembed&amp;url=http%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3DkNMffxJ2f7E&amp;image=https%3A%2F%2Fi.ytimg.com%2Fvi%2FkNMffxJ2f7E%2Fhqdefault.jpg&amp;key=a19fcc184b9711e1b4764040d3dc5c07&amp;type=text%2Fhtml&amp;schema=youtube" width="854" height="480" frameborder="0" scrolling="no"><a href="https://medium.com/media/105b4b2a336409cd816c575913082bd7/href">https://medium.com/media/105b4b2a336409cd816c575913082bd7/href</a></iframe><p>Specifically, Salk’s new cancer initiative will focus on five ways to eliminate the disease: cutting the metabolic supply lines that provide fuel to tumors; disrupting the inflammatory barriers protecting cancer cells; decoding cancer’s genomics to reprogram malignant cells back to normal; mobilizing the immune system to recognize and attack cancer; and developing sophisticated methods to strike cancer’s many vulnerabilities simultaneously. By targeting these five areas, Salk scientists continue the Institute’s legacy of discovering foundational biological mechanisms to understand — and ultimately conquer — cancer.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*G0rXDdBOhan7shLsTjvSAw.png" /></figure><p>To continue growing, tumors must constantly find new food sources. Scientists have known for more than a century that tumors rewire their metabolisms to get more energy. However, it’s only in the past few years they’ve recognized what a powerful weapon metabolism can be.</p><p>Shaw has been investigating this metabolic connection for more than a decade. He discovered that the altered LKB1 gene, which is often mutated in lung cancer, activates a metabolic master switch. This unforeseen connection between cancer and metabolism offered a new therapeutic strategy: hit cancer through its food supply.</p><p>Like normal cells, tumors rely primarily on glucose for energy. But cancer always has a backup plan. Should glucose run short, tumors rewire themselves to use the amino acid glutamine for fuel. However, once a tumor commits to a secondary energy source, it can have trouble reversing the process. Healthy cells are more flexible. Shaw and others believe they can take away these sources, one at a time, and gradually force cancer into a corner.</p><p>“Normal cells aren’t metabolically stressed — they can flip back and forth between using different food sources,” says Shaw, who holds the William R. Brody Chair. “Tumor cells are naturally more constrained in their metabolism. You’re confining the tumor metabolically (by taking away its energy sources), and when you get it there, you hit the trap door.” Another example of tripping metabolic trap doors is by targeting mitochondria, the cells’ power stations. “We have discovered that specific cancer gene mutations make cells sensitive to mitochondrial drugs, including the diabetes drug Metformin.”</p><p>Shaw’s metabolic strategy shows great promise and underscores Salk’s overall approach: identify cancer’s many vulnerabilities and exploit them. Because each patient’s disease is different, these approaches can be mixed and matched based on a tumor’s genetic profile.</p><p>“We need to think about how we use drug strategies to treat each individual patient’s subset of cancer,” says Shaw. “One would be targeted therapeutics, another would be immunotherapy drugs and a third could be taking out the metabolic Achilles’ heel. These would be viable strategies with less toxicity.”</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*Ninc_FPlVKxW-154Mgc-iA.png" /></figure><p>As cancer develops, the body responds, sending inflammatory signals to fight the invader. Acute inflammation is part of the body’s healing process. But if it persists, inflammatory mechanisms can do even more harm.</p><p>“Cancer has been referred to by pathologists as a wound that will not heal,” says <a href="https://www.salk.edu/scientist/geoffrey-wahl/">Geoffrey Wahl</a>, a professor in Salk’s Gene Expression Laboratory. “The body is trying to restore balance to the cancerous organ, but it can’t do that because of all the genetic and epigenetic changes that have led to deranged growth.”</p><p>Wahl has been studying this interplay between tumors and the body’s response systems and has made a startling discovery: in this hyperinflammatory environment, cells change — a lot.</p><p>The lab’s work led them to a gene called SOX10, which is normally associated with early development. Inflammatory signals intended to heal cancer can turn on SOX10 signals, which can change cells in a variety of ways. Normal cells tend to stay put, but under SOX10’s influence, they revert to early, developmental states, becoming mobile and, ultimately, invasive.</p><p>These processes play a big role in triple-negative breast cancer, which is even more disorderly than other forms of the disease. In this biological melee, cells lose p53, the quality-control mechanism that helps keep genomes intact.</p><p>“Because of this persistent wounding environment, some of these cells start to reprogram themselves,” says Wahl, who holds the Daniel and Martina Lewis Chair. “They get reprogrammed into fetal antecedents, which are selected to survive in this chaotic environment.”</p><p>By illuminating this biology, Wahl hopes to find markers that can differentiate reprogrammed cells from normal tissue. Once these aberrant cells can be separated, they can be selectively targeted.</p><p>Inflammation also plays a major role in pancreatic cancer, which creates a protective shell that blocks both immune cells and chemotherapy.</p><p>“Pancreatic cancer is like its own ecosystem,” says <a href="https://www.salk.edu/scientist/ronald-evans/">Ronald Evans</a>, professor and director of the Gene Expression Laboratory and holder of the March of Dimes Chair in Molecular and Developmental Biology. “Once it’s contained in this shell, it’s difficult for drugs to reach it. Instead of directly attacking the cancer, we had the idea to attack the ecosystem that surrounds it.”</p><p>Evans’ lab modified vitamin D, transforming it into a molecule that can alter the environment supporting pancreatic cancer’s protective shell. By softening the shell, this modified vitamin D drug makes tumors vulnerable to attacks from the immune system or chemotherapy. The drug is currently in clinical trials in combination with Merck’s immunotherapy Keytruda. The lab recently received a $2.5 million Catalyst grant from Stand Up To Cancer to advance this work.</p><p><a href="https://www.salk.edu/scientist/tony-hunter/">Tony Hunter</a>, American Cancer Society Professor and holder of the Renato Dulbecco Chair, is one of many researchers collaborating with Evans. Hunter started his career investigating the signaling mechanisms that drive cancer, providing the foundational knowledge for an entirely new class of cancer drugs (see sidebar “From basic discovery to effective treatment”). In this case, his lab is focusing on the cross-talk between pancreatic tumors and their surrounding cells, called stroma.</p><p>“Stromal cells produce hundreds of proteins, including LIF, a protein that strongly stimulates tumor cells,” says Hunter. “Tumor cells make their own factors that stimulate the stroma, so it’s reciprocal.”</p><p>Hunter is working with a company called Northern Biologics, which has developed an antibody against LIF that will soon enter clinical trials.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*zWTpqKn2Olh7dNRsWFoEmQ.png" /></figure><p>When Jonas Salk founded the Institute, he wanted to encourage foundational research to spark new ideas and therapies.</p><p>“He had this vision,” says <a href="https://www.salk.edu/scientist/martin-hetzer/">Martin Hetzer</a>, professor in the Molecular and Cell Biology Laboratory and Salk’s Chief Science Officer. “Let’s address the most prominent problems, understand the biology on the deepest level, bring people here who will work across disciplines and let them do what interests them.”</p><p>This approach produces results. In 1996, American Cancer Society Professor of Molecular Biology <a href="https://www.salk.edu/scientist/inder-verma/">Inder Verma</a> was trying to put genes into cells. He realized a neutered HIV virus might be an excellent delivery vehicle. Fast-forward 22 years and the FDA approved Kymriah, a CAR-T therapy. These customized treatments remove T-cells from a patient’s blood, add genes to make them more aggressive against certain blood cancers and infuse them back into that patient. Kymriah, and other CAR-Ts, use Verma’s approach to add those all-important genes.</p><p>His work has also clarified how the mutated breast cancer gene BRCA1 raises the risk of breast and ovarian cancers and why glioblastoma (GBM) is so difficult to treat. Genetic changes in GBM cells make them resemble embryonic stem cells, meaning they can become virtually any type of brain cell, albeit diseased ones. This acquired trait gives them an enormous survival advantage.</p><p>“Every cell in GBM basically becomes a stem cell,” says Verma. “Even if the surgeon has removed 99.999 percent of the tumor, what remains will come back.”</p><p>This adaptability has grave consequences. Oncologists have prescribed a drug called Avastin against GBM, with limited success. Avastin targets the VEGF gene, which helps the body produce new blood vessels, to cut off tumor blood supplies. But GBM adapts.</p><p>The tumor develops new blood vessels independent of VEGF, so Avastin is no longer relevant.</p><p>But the lab has pioneered a new strategy against glioblastoma. They showed that these tumors express many genes associated with NF-kB, a master switch that turns on many tumor-associated genes. The lab then developed a peptide (a piece of a protein) that can shut down NF-kB’s ability to activate these genes and maintain the glioma-inducing stem cells. When GBM mice receive this peptide, they survive for 70 days, compared to 30 days in the controls. That’s the equivalent of 20 years in humans.</p><p>Given that most GBM patients live only 14 to 18 months after diagnosis, this could be a huge advance. Salk is forging links with biotech companies to move this potential drug strategy towards the clinic.</p><p>Research at Salk has shown that genomes can be modified in many ways. The Hetzer lab studies a process called chromothripsis, in which DNA and its proteins, coiled into packages called chromosomes, get separated from the nucleus and pulverized. The resulting DNA is like a mini-Frankenstein — everything is out of place.</p><p>“This monster chromosome is then reincorporated into the main nucleus,” says Hetzer, who holds the Jesse and Caryl Philips Foundation Chair. “In most cases, these cells will die, but sometimes it gives cells a growth advantage. Up to 50 percent of bone cancers have chromothripsis.”</p><p><a href="https://www.salk.edu/scientist/jan-karlseder/">Jan Karlseder</a>, professor in the Molecular and Cell Biology Laboratory, is investigating telomeres, repeating DNA sequences on chromosomes that keep them from unravelling, kind of like plastic tips on shoelaces. In normal cells, telomeres get shorter with each cell division. When they get too short, a signal tells the cells to self-destruct. Cancer has found a way around this timekeeper, granting these cells a form of immortality.</p><p>“By inhibiting telomere maintenance, we can make immortal cancer cells mortal again,” says Karlseder, who also holds the Donald and Darlene Shiley Chair. “After a certain number of population doublings, they start to die. It is possible that targeting telomere maintenance could be a fairly universal cancer treatment option.” As Karlseder continues to investigate telomere function in healthy and malignant cells, he hopes to identify new molecular targets for treatment. Eventually, selectively modulating telomere maintenance might be used to prevent cancer.</p><p><a href="https://www.salk.edu/scientist/diana-hargreaves/">Diana Hargreaves</a>, assistant professor in Salk’s Molecular and Cell Biology Laboratory, investigates an emerging scientific discipline to better understand cancer genomes: epigenetics. These patterns of molecular markers on DNA help determine whether a gene is turned on or off. The epigenome is akin to software that tells hardware how to run. It instructs cells containing the same DNA, for example, whether to become muscle or brain or bone tissue. Unfortunately, tumor cells have caught on and harness the epigenome to selectively turn on cancer-promoting genes. In many tumors, the enzymes that place these molecular flags, or regulators, are mutated, giving cancer cells an added advantage. To eliminate cancer without harming normal cells, Hargreaves wants to target these epigenetic regulators.</p><p>“This gives us a window of opportunity,” says Hargreaves, who holds the Richard Heyman and Anne Daigle Endowed Development Chair. “We can look into how to drug the cancer epigenome. One method is to target the enzymes that place the flags, resetting the epigenome to normal levels, and lowering the activity of cancer-promoting genes.”</p><p>By focusing on ovarian and gynecological cancers, in which epigenetic enzymes are frequently mutated, Hargreaves’ team seeks to understand how these mutations alter gene expression and whether they can be targeted to treat ovarian cancer. In particular, the lab is looking at an epigenetic regulator called the SWI/SNF complex, which unpacks and unwinds DNA from structural proteins to alter DNA accessibility and,<br>in turn, which genes are activated.</p><p>The SWI/SNF complex can assume different forms through various combinations of individual subunits. One of these, called ARID1A, is mutated in many solid tumors, including ovarian, bladder and colorectal. By exploring the different activities of these complexes in normal and cancer settings, the lab hopes to identify new ways to target these cancers.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*MARTCQCUnHhVrIrasHKqBA.png" /></figure><p>As cancers evolve, they learn to disable the immune system, sending signals that fool immune soldiers called T-cells, and other components, into thinking tumors are healthy tissue. Drugs called checkpoint inhibitors interfere with those signals, revving up the immune response. It was a checkpoint inhibitor, combined with radiation, that put former President Jimmy Carter’s melanoma into remission.</p><p>These therapies can be exceptionally effective, but only for around 25 percent of patients, fewer in some cancers. The race is on to better equip the immune system to tackle tumors.</p><p><a href="https://www.salk.edu/scientist/susan-kaech/">Susan Kaech</a>, professor and director of the NOMIS Center for Immunobiology and Microbial Pathogenesis, is working to understand how tumors evade detection by the immune system and ultimately reverse that process.</p><p>“The drugs that stimulate the immune response are having such beneficial effects for patients, we know they are going to be part of, if not the future of, cancer treatment,” says Kaech, holder of the NOMIS Foundation Chair. “We are looking to uncover the pathways that tumors are using to suppress<br>T-cells, as well as ways to manipulate those to turn suppressed responses into effective responses.”</p><p>Kaech is one of Salk’s newest faculty, joining the Institute this past summer from Yale University. Her lab seeks to understand how immunity works on the most basic levels. How does immune memory form? Why do T-cells infiltrate some tumors and not others? Can we turn macrophages, cleanup cells that consume and destroy other cells, into cancer killers? How do nutrient-starved regions around tumors affect glucose-hungry T-cells?</p><p>If that last question suggests a link to Shaw’s work on tumor metabolism, that’s no accident. Kaech looks forward to collaborating with Shaw, Evans and others on a variety of projects, uniting different disciplines to get a more complete picture of these diseases and possible therapies.</p><p>“I love collaborating and working with researchers who think about problems from different perspectives,” says Kaech. “This is the fabric of Salk, and I am very excited to be a part of that.”</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*dHso_xG4k9DeVjpSmCMZpw.png" /></figure><p>Many new therapies target tumors based on specific mutations. The challenge is figuring out which patients will respond to a particular drug. Salk scientists are working to solve that problem: first, by understanding the mutations in each patient’s cancer and the consequences of those mutations, and second, by determining which targeted therapies will do them the most good.</p><p>Edward Stites, assistant professor in the Integrative Biology Laboratory, is using math to solve this problem. As a medical doctor, Stites has a unique perspective on both research and treatment. He regularly participates in tumor boards at Moores Cancer Center at UC San Diego Health in La Jolla, where clinicians develop patient-care plans based, in part, on the mutations in their tumor DNA. This helps him identify the most pressing clinical needs for cancer research. His main target is the RAS oncogene, the major mutation in approximately 30 percent of all cancers and 95 percent of pancreatic tumors.</p><p>“Scientists have measured almost everything that can be measured about this protein over the past few decades,” says Stites. “The data is enormous, but no one person can look at all those numbers and make sense of them. We are developing computer models to simulate what we think is happening and using these simulations to generate new ideas.”</p><p>Occasionally, this mathematical modeling produces unexpected insights into cancer. Every gene has two copies (alleles), one from each parent. In most patients, only one RAS copy is mutated. For decades, scientists thought the normal copy didn’t matter in cancer, but Stites showed the hyperactive mutant copy makes the normal allele more active. Now, scientists are focusing on both alleles to better understand how they interact.</p><p>Genes can also be mutated in different ways; RAS has around 20 variations. These various forms can affect which patients respond to treatment. Stites wants to make sure every patient receives the right combination of therapies.</p><p>“Right now, there are guidelines for who should get a treatment and who shouldn’t,” says Stites. “I think those guidelines are mostly right but not quite. There are likely patients who would benefit from a treatment but don’t receive it, and there are patients who get a treatment that won’t help them. We are using our computational models to better understand the relationship between mutations and response so that patients ultimately receive the right treatment.”</p><h3>Conquering cancer…as a team</h3><p>Any cell biologist will tell you that a protein’s shape impacts its function. The same is true of research institutes. Louis Kahn’s iconic architecture is more than just pleasing to the eye — it also helps drive discovery. Salk’s design ensures that some of the world’s most significant experts in cancer biology, genomics, metabolism, plant biology and many other fields run into each other often, and these courtyard consults make a difference.</p><p>“It’s the cross-fertilization of fields that has been the secret to almost all of these breakthroughs at Salk,” says Shaw. “If you look at the papers, many of the breakthroughs have been from labs that are physically right next to each other.”</p><p>Chat with any Salk scientist, from principal investigators to graduate students, and they will inevitably turn to the collaborations that help make them successful.</p><p>If there is one universal truth about cancer, it’s that the disease is complicated. Successful approaches must attack several mechanisms. This makes collaborations between multiple disciplines to identify cancer’s most profound vulnerabilities, as well as the molecules and approaches that will attack them, all the more essential. In addition to collaborating within Salk’s walls, Institute researchers will continue to work closely with hospitals, universities, biotechs and pharmaceutical companies to move new agents into the clinic.</p><p>“The collaboration that goes on at the Salk is essential to take on a disease as complex as cancer,” says Hetzer. “There are so many mechanisms that need to be addressed, and only by throughly understanding them all — in context — can we really get to the root of the problem.”</p><p>To read more about the Conquering Cancer Initiative, please visit: <a href="https://www.salk.edu/conqueringcancer">www.salk.edu/conqueringcancer</a></p><p><a href="http://inside.salk.edu/">Click here</a> to view the most recent issue of Inside Salk.</p><p><strong>About the Salk Institute for Biological Studies:</strong></p><p>Every cure has a starting point. The Salk Institute embodies Jonas Salk’s mission to dare to make dreams into reality. Its internationally renowned and award-winning scientists explore the very foundations of life, seeking new understandings in neuroscience, genetics, immunology, plant biology and more. The Institute is an independent nonprofit organization and architectural landmark: small by choice, intimate by nature and fearless in the face of any challenge. Be it cancer or Alzheimer’s, aging or diabetes, Salk is where cures begin.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=e597b537b80d" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Beyond DNA: Unlocking the Secrets of the Epigenome]]></title>
            <link>https://medium.com/@salkinstitute/beyond-dna-unlocking-the-secrets-of-the-epigenome-4a57cf43e476?source=rss-25ad4702628b------2</link>
            <guid isPermaLink="false">https://medium.com/p/4a57cf43e476</guid>
            <category><![CDATA[science]]></category>
            <category><![CDATA[dna]]></category>
            <category><![CDATA[epigenetics]]></category>
            <category><![CDATA[dna-sequencing]]></category>
            <dc:creator><![CDATA[Salk Institute]]></dc:creator>
            <pubDate>Sat, 03 Jun 2017 00:25:45 GMT</pubDate>
            <atom:updated>2017-06-03T00:25:45.459Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*MgFir0VihQnzuQTSIrl2Jw.png" /><figcaption>Beyond DNA: Unlocking the Secrets of the Epigenome</figcaption></figure><h3>A layer of regulatory information on top of DNA is proving to be as important as genes for development, health and sickness.</h3><p>Why is a queen bee enormous compared to her worker bees? Why does one flower have petals that grow in a star-shape while another genetically identical flower forms petals in a mirror reflection? And how can two mice differ in color and shape even though they have the same DNA? In these cases and others, the two comparisons are genetically identical, possessing the same DNA code. So why does the same genetic code lead to very different outcomes?</p><p>Welcome to the epigenome. Many people are now familiar with the genome — a term used to denote the entirety of a person’s genetic code — but the epigenome, a lesser known, secondary layer of information that coats the genome, may be just as important in making us who we are.</p><p>This layer, made up of proteins and other molecules that bind onto the genes like tags, is proving to play a vital role in development, health and disease. Some have likened the epigenome to a symphony, where the DNA sequence is sheet music that can be expressed in vastly different ways through the direction of epigenomic regulators.</p><p>“The notes are identical but musicians can change the tempo or use a variety of instruments for different effects,” says <a href="http://www.salk.edu/scientist/joseph-ecker/">Joseph Ecker</a>, director of Salk’s Genomic Analysis Laboratory and codirector of California Institute for Regenerative Medicine (CIRM)’s The Center of Excellence for Stem Cell Genomics. “Likewise, these epigenetic factors along with other factors in cells each ‘play’ a role in how and when cells are to become heart tissue versus a liver, for example.”</p><p>The genome is constantly assailed by cellular molecules that temporarily turn genes on or off in response to the environment or in preparation for cell division. This is a stark contrast to more permanent changes like a mutation, where the gene itself is irreversibly changed.</p><p>The epigenome (whose precise definition can vary depending on who you talk to) can have both temporary and long-term effects on gene expression. It often consists of modifications to the genome that can persist for a time but are still ultimately reversible — able to fall off and leave the genes as they were.</p><p>One intriguing aspect of the epigenome is that epigenetic changes can be heritable, passed on from cell to cell as they divide and sometimes from parent to offspring. The epigenome may be affected by diet, activities like exercise or smoking, development and environment, suggesting that your lifestyle — and thus, epigenome — could have implications not just for you but also for your potential children or even grandchildren. Studies in mice, for example, suggest that how attentive a mother is to her pups after birth affects their epigenome, which later dictates levels of hormones and stress they experience as adults. The epigenome may also explain why some humans born in stressful or traumatic environments experience higher levels of sickness later in life, even in a safe and healthy setting.</p><p>“So much more research is necessary to determine if there is a causal link between cases where epigenetic variation has been observed and any health, diet or disease associations,” says Ecker, whose group participates in the NIH Roadmap Epigenomics Mapping and ENCODE (ENCyclopedia Of DNA Elements) Consortium. Both are efforts to map the epigenome and its intricate workings to understand how it influences the cell in development and how it changes in disease. More and more, scientists are showing that certain epigenomic changes can have a profound impact on everything ranging from cancer to diabetes to mental disorders. Scientists are banking on the idea that learning how to read — and manipulate — the epigenome may help us unlock entirely new suites of treatments.</p><blockquote>To explain how the epigenome works, some have likened it to a symphony: the sheet music (genome) is the same, but can be expressed in vastly different ways depending on the group of players and their instruments (epigenome).</blockquote><blockquote><strong>WHAT IS AN EPIGENOME? The epigenome is a secondary layer of molecular information that sits on the (‘epi’) of the genome to affect what genes are activated or silenced. The epigenome can change over time </strong>— <strong>during development or in the presence of disease, for example, and may provide new clues to targeting disorders.</strong></blockquote><p><strong>MAPPING THE MUSIC</strong></p><p>In the early 2000s, the announcement of the completion of the Human Genome Project led to unprecedented insights into how genetics influence health and disease. While fully sequencing the human genome promised to move us closer to personalized medicine that could individualize treatments to better cure disease, it turned out that mapping out the entire sequence of adenine, thymine, cytosine and guanine (A, T, C and G) pairs provides only a piece of the picture. A next step is to chart the epigenome — one component of which is the pattern of chemical tags called methyl groups that stud DNA to influence whether or not genes are activated.</p><p>What do these methyl tags do exactly? These branched molecules of carbon and hydrogen typically are attached to cytosine (the “C” of DNA base pairs) and tell other proteins to go away — or, in some cases, to gather — turning the attached gene off or on. Acting as on/off switches or stop-and-go signals, millions of methyl tags pepper the genomes of your cells.</p><p>Ecker first became intrigued by the epigenome while studying <em>Arabidopsis thaliana</em>, a small flowering plant used for basic plant biology research. He and his colleagues wanted to know how many <em>Arabidopsis </em>genes were controlled by DNA methylation. But while methylation has been studied for decades, there was no good way to get a snapshot of all the methylation marks in a cell’s DNA. So Ecker created one.</p><p>His lab designed a method called MethylC-Seq, which entails several chemistry techniques that break DNA into small pieces to process them through high-speed computers and technology such as sequencers built by the San Diego-based company Illumina. The resulting data allows scientists to, for the first time, see and quantify those methyl marks on the 3-billion-base genome. “MethylC-Seq allows us to extract that information from the invisible (methylated cytosine) and make it visible,” says Ecker, who is also a Howard Hughes Medical Institute and Gordon and Betty Moore Foundation investigator.</p><p>MethylC-Seq displays this methylation in patches of yellow, letting Ecker’s team compare different cells in one organism or across organisms to search for links, for instance, between aberrant DNA methylation and disease. Ecker’s methods have led to the first maps of the epigenome for plants and also animal cells, including humans, which has shown evidence that methylation increases from birth to adulthood. His major publication in 2015 in <em>Nature </em>provided, for the first time, details into the epigenome of a variety of tissues from organ donors of different genders and ages.</p><p><strong>WHAT’S IN A BRAIN?</strong></p><p>In 2013, Ecker and his neuroscience collaborators Margarita Behrens and <a href="http://www.salk.edu/scientist/terrence-sejnowski/">Terrence Sejnowski</a> published work in the journal <em>Science </em>showing something surprising. They had mapped the pattern of millions of methylation changes in the brain’s frontal cortex using human tissue. Methylation usually occurs on the DNA base cytosine (“C”) when it is adjacent to guanine (“G”). This epigenomic map of a healthy human brain revealed a type of methylation not normally seen in the body: methyl tags in neuronal cells were binding to DNA in places other than C. His team found that this alternative methylation (called non-CG) starts at birth and increases throughout early adulthood. Ecker and others suspect that abnormal patterns of methylation of this type might be associated with mental disorders like schizophrenia, whose symptoms don’t manifest until early adulthood.</p><p>“We found a major difference in the epigenome of neurons which is an accumulation of a new kind of methyl mark that we didn’t even know existed before in neurons,” says Behrens, a Salk senior staff scientist. “This non-CG methylation accumulates from birth through adolescence during a critical period of brain maturation when connections are being made.”</p><p>When it comes to the brain, other studies have shown that environmental factors — medicine, diet, age, stress and chemical exposure — can change methylation in brain cells. Ecker and others are examining this global epigenomic reconfiguration during brain development to uncover potential ties to mental disorder. In one study, they are examining the effects of viruses and chemical exposure in animal models to see how environment changes this new type of methylation in brains during development. In another, his team has begun to map the epigenome of neurons from those with Alzheimer’s.</p><p>“Even if these epigenetic events are not causative for these disorders, they can provide useful markers of disease progression,” Ecker says. “And because methylation and other epigenomic changes are in essence temporary, there may be ways to tweak the epigenomic code to help treat diseases of the brain and the body.”</p><p><strong>THE SHAPE OF DNA</strong></p><p>Salk Assistant Professor <a href="http://www.salk.edu/scientist/julie-law/">Julie Law</a> focuses on another aspect of the epigenome: the complicated and cryptic realm of chromatin, which is the dynamic combination of proteins, small RNAs and other molecules that surround DNA and which plays key roles in controlling its expression and stability.</p><p>“We are trying to understand how you get different outcomes from the same DNA,” says Law. “Epigenetic modifications are one way in which you can achieve this diversity to the genome in a manner that doesn’t change the underlying DNA sequence. But what we don’t understand is how epigenetic modifications target different places in various cells and are recognized and translated into desired responses.”</p><p>Part of the answer may be found in an epigenome change called chromatin remodeling, where proteins alter how the DNA is stored. Human DNA in a single cell is enormously long — six feet — and folds with proteins into intricate packages (chromatin) to fit within a nucleus. Imagine rolling and storing sweaters and mothballs into sealed vacuum bags to both keep them safe and make room for storage. In a similar way, the packaging of the DNA begins with histone proteins, which act as spools to wind DNA. The histones, DNA and other proteins are then further packaged into larger chromatin. Like sweaters hanging in the front of a closet, genes on the outside of chromatin are more easily accessed and usable than those stored deeply away.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/683/1*Fr4xVYGRz--iFZf_O-JZaw.jpeg" /><figcaption>If we can better understand protein complexes involved in chromatin remodeling and how mistakes in making specific regions of the genome more or less accessible leads to cancer, we can develop targeted treatments.</figcaption></figure><p>Proteins that sit on top of the chromatin and control its spatial arrangement play an integral role in what genes are used or not and, similar to methyl tags, can have grave effects on health and disease. Adding chemical markers (methyl tags and others) to histone proteins can result in rearranging the chromatin, dictating which genes are ignored and which are turned on.</p><p>To understand these epigenetic factors, Law uses the <em>Arabidopsis </em>plant that, unlike mammals, is more tolerant of changes to the epigenome. She’s turned her attention to several newly identified families of proteins involved with DNA packaging and gene expression, called chromatin-binding proteins. She is striving to determine the epigenetic marks recognized by these protein families as well as identify their interacting partners and their effects on gene expression. Although Law’s research utilizes a plant model, her findings will also hold lessons for human biology as many of the genes involved in adding or removing epigenetic marks are the same in plants as in mammals.</p><p><a href="http://www.salk.edu/scientist/graham-mcvicker/">Graham McVicker</a>, a Salk assistant professor who studies the human genome and chromatin, says, “It’s as if the genome is a big landscape and the cell can plunk down flags — DNA methylation marks or histone modifications — to indicate which parts of the landscape have specific functions.” McVicker, who aims to understand how differences in the genome sequence affect our cells at a molecular level, adds that the genomes of unrelated individuals only differ by about one base in every thousand and that most of these differences have no function. “One way to understand which genetic differences are important is to look for the ones that are associated with the expression of genes or changes in histone modifications,” he says. “The goal is to understand how genetic differences affect gene expression or epigenetics and ultimately how these differences contribute to human traits and diseases.”</p><p><strong>UNTANGLING CANCER</strong></p><p>Salk Professor <a href="http://www.salk.edu/scientist/beverly-emerson/">Beverly Emerson</a> drills into the epigenome’s mechanistic processes from another angle: cancer.</p><p>In the last few decades, researchers have shown that changes in the epigenome are tied to many types of cancer through projects like ENCODE or NIH’s Cancer Genome Atlas (TCGA) Network, which compares genomes and epigenomes of normal and cancerous cells. Despite these efforts, it is difficult to untangle causes from correlations when it comes to epigenetics and cancer.</p><p>“The cell has a whole constellation of proteins to read and decode its DNA. Epigenetics is an elaborate way to allow the DNA coding sequence to be read in a manner contingent upon physiological signals,” says Emerson, holder of Salk’s Edwin K. Hunter Chair. “But when a DNA base change or a mutation occurs, epigenetic changes can promote the overgrowth of cancer or suppress the immune system.”</p><p>The body’s cells undergo changes in signaling to their genomes all the time: when you eat, when you get sunburnt, when you feel certain emotions. Emerson’s team is trying to distinguish those normal changes of the epigenome versus cancer-causing changes that result from chronic stress to the cell.</p><p>“There are so many changes in a cancer cell that often you don’t know what the driver was,” says Emerson. “Cancerous cells are already massively epigenetically modified, but we want to know how epigenetic changes and alterations in transcriptional programming primes cells to become cancerous.”</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/184/1*LttfRczzIPpK1lArsHUKow.jpeg" /><figcaption>Many molecules act on the genome without changing the genes themselves. While DNA methylation is a common epigenetic change to the genome, other factors are able to influence gene expression, ultimately affecting health and disease.</figcaption></figure><p>By studying normal breast tissue samples and observing how those cells respond to prolonged stress, she hopes to understand how cells turn into breast cancer. To do this, she examines how alterations in DNA methylation and the cells’ chromatin regulators lead to critical tumor suppressant genes becoming rapidly silenced.</p><p>“Our hypothesis is that such abnormal cells accumulate with time and age. They’ve changed their epigenomic programming and are more vulnerable to becoming cancerous,” says Emerson. “A gene can become permanently locked into a repressed state through methylation, which is a problem if the gene happens to be a tumor suppressor or related to immune function.”</p><p>One way in which a gene can get locked into a repressed state is by mutations to epigenetic modifiers themselves, which is increasingly observed in the sequencing of human cancers. Salk Assistant Professor <a href="http://www.salk.edu/scientist/diana-hargreaves/">Diana Hargreaves</a> is examining one such target in cancer, an epigenetic regulator called the SWI/SNF complex, which unpacks and unwinds DNA from chromatin to alter gene accessibility. Many pieces or subunits of the SWI/SNF complex are mutated in cancer, including ARID1A, which is mutated in ovarian, bladder, lung and colorectal cancers. Hargreaves is exploring the different activities of the SWI/SNF complex in normal and disease settings in order to figure out how to target ARID1A mutant cancers.</p><p>“We now know that mutations in chromatin remodeling proteins, such as ARID1A, can shift the balance of epigenetic modifiers at key tumor suppressor genes, leading to changes in histone modifications and gene accessibility that repress these genes. In the context of growth signals, this can rapidly lead to cancer,” says Hargreaves. “If we can better understand how mutations in protein complexes involved in chromatin remodeling prime the cell to become cancerous, we can begin to develop targeted treatments for SWI/SNF mutant and potentially other cancers.”</p><p>Researchers are already testing and applying drugs that target the epigenome by stripping away methylation in hopes of removing the tags that have silenced tumor suppressant genes. (One example is the drug temozolomide, used for treating brain tumors called glioblastoma.) However, there are some obstacles: such a treatment would strip away methylation on the rest of the genome, potentially leading to additional issues. Secondly, methylation is only one aspect of the epigenome; proteins that regulate chromatin are also often mutated in cancer. Nevertheless, refining ways to target methyl tags and other epigenetic regulators could be a boon for treatments in part because the epigenome is more reversible and malleable than say, a genetic mutation.</p><p><strong>CHARTING THE EPIGENOME’S REACH</strong></p><p>So far, researchers have shown that some types of modifications to histone proteins, cytosine methylation and molecules called small RNAs can be inherited in mice, flies and plants, for example, but it’s unclear to what extent epigenetics is inherited in people. “Just as everything — disease, obesity, depression — used to be blamed on the genome, now you will see all sorts of claims about the epigenome and I would not believe most of it,” Ecker says. “What I would say is that we’re really just at the beginning of understanding the epigenome and heritability but if there is the possibility that your diet or environment could affect your children or grandchildren, that will be important to know and exploring the molecular mechanisms using model systems may help us to understand these phenomena better.”</p><p>Aside from exploring methods of inheritability, Ecker and others are now making a slew of maps of normal and disease states to generate comprehensive epigenomic references for everything from neurodegenerative and developmental disorders to metabolic diseases like diabetes as well as cancer. In one study, Ecker and Salk Professor <a href="http://www.salk.edu/scientist/ronald-evans/">Ronald Evans</a> are studying how exercise might affect your epigenome. In another effort recently funded by the NIH, Ecker is researching whether viruses can act on the epigenome during development to cause autism.</p><p>“At Salk, we have scientists interested in understanding epigenetics related to cancer, neuroscience, regenerative medicine and other fields, as well as researchers who have the potential to make small molecule drugs to target the epigenome,” says Ecker. “We’re really at the very beginning and it’s the interplay of these areas of specialties that is going to advance the science and help us understand how the epigenome is affected by development, nutrition, disease and aging.”</p><p><a href="http://inside.salk.edu/">Click here</a> to view the most recent issue of Inside Salk.</p><iframe src="https://cdn.embedly.com/widgets/media.html?url=https%3A%2F%2Fpowered.by.rabbut.com%2Fp%2FcLiZ%3Fc%3D0&amp;src=https%3A%2F%2Fpowered.by.rabbut.com%2Fp%2FcLiZ%3Fc%3D0&amp;type=text%2Fhtml&amp;key=a19fcc184b9711e1b4764040d3dc5c07&amp;schema=rabbut" width="500" height="500" frameborder="0" scrolling="no"><a href="https://medium.com/media/b4fca03ef76f2f8979c8390ad8580f09/href">https://medium.com/media/b4fca03ef76f2f8979c8390ad8580f09/href</a></iframe><p><strong>About the Salk Institute for Biological Studies:</strong></p><p>Every cure has a starting point. The Salk Institute embodies Jonas Salk’s mission to dare to make dreams into reality. Its internationally renowned and award-winning scientists explore the very foundations of life, seeking new understandings in neuroscience, genetics, immunology, plant biology and more. The Institute is an independent nonprofit organization and architectural landmark: small by choice, intimate by nature and fearless in the face of any challenge. Be it cancer or Alzheimer’s, aging or diabetes, Salk is where cures begin.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=4a57cf43e476" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[A SONG IN BLOOM]]></title>
            <link>https://medium.com/@salkinstitute/a-song-in-bloom-f119ea49f942?source=rss-25ad4702628b------2</link>
            <guid isPermaLink="false">https://medium.com/p/f119ea49f942</guid>
            <category><![CDATA[salk-institute]]></category>
            <category><![CDATA[biology]]></category>
            <category><![CDATA[plantbiology]]></category>
            <category><![CDATA[plant-science]]></category>
            <category><![CDATA[science]]></category>
            <dc:creator><![CDATA[Salk Institute]]></dc:creator>
            <pubDate>Sat, 20 May 2017 13:13:19 GMT</pubDate>
            <atom:updated>2017-05-20T13:13:19.302Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*6-XjdXnNPOFiuQO5rnksmA.jpeg" /></figure><p>When many of us look at a plant, we see a collection of stems and leaves. If it’s flowering, we might notice the shape or the color of its blossoms. When <strong>Liang Song</strong> looks at plants, she sees millions of years of evolution. And she marvels at all the adaptations that particular plant has had to make through evolutionary history to be growing where she has found it, on a hike or while traveling in a foreign land.</p><p>Song, who grew up in China, has always been fascinated by flora. As a young child one of her favorite games was collecting different flowers and presenting them on a plate, like a chef with a signature dish. Later, as an undergraduate, she studied ecology. While surveying the spread of <em>Solidago canadensis</em>, an invasive plant from North America, Song was introduced to some techniques from molecular biology. Always interested in learning novel approaches to address fundamental scientific questions in a new way, she decided to get her PhD in that field.</p><p>Today, as a research associate in<a href="http://www.salk.edu/scientist/joseph-ecker/"> Joseph Ecker’s</a> lab, Song studies the crosstalk of plant hormones (“phytohormones”) in the weed <em>Arabidopsis thaliana</em>. Specifically, she employs high- throughput sequencing to examine the myriad transcripts, or protein- making instructions, produced when the phytohormone abscisic acid (ABA) begins cascades of chemical chatter in response to an environmental stressor, such as drought.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/869/1*acTy1gVIr20fleKAOdI9mA.png" /><figcaption>Above are photographs Song has taken on her travels. She says she tries to understand places through their plants and loves photographing them and learning about them from the locals.</figcaption></figure><p><a href="http://www.salk.edu/news-release/molecular-conductors-help-plants-respond-drought/">In a recent study published in <em>Science</em></a>, Song tracked real-time changes in genetic activity in <em>Arabidopsis’</em> response to ABA, and found that, in the face of environmental hardship, plants employ a small group of proteins that act as conductors to manage their complex responses to stress. She discovered new stress-response genes via snapshots of key proteins binding to DNA throughout the genome. The results may help in developing new agricultural technologies to optimize water use in plants so that they can better adapt to drought and other climate-related stressors.</p><p>Snapshots, as it happens, are another passion of Song ’s. In her spare time she is an avid photographer who particularly enjoys capturing images of flora she encounters when she travels. Every time she goes to a new place, she tries to understand the local plants through photography. One of the most memorable of late was a columbine (pictured above) she came across while hiking in Utah’s Bryce Canyon. Amid a tumble of rocks in the arid landscape was a “cute little flower with tiny leaves.”</p><p>While taking the shot, Song thought about how the smallness of the leaves helps the plant conserve water. She was impressed by the delicacy of the columbine’s stem, which somehow managed to support a giant bloom, an act of defiance in the harsh terrain. For Song, photography and plant biology, travel and science — all are ways to better understand the world — and her place in it.</p><p>Today, as a research associate in<a href="http://www.salk.edu/scientist/joseph-ecker/"> Joseph Ecker’s</a> lab, Song studies the crosstalk of plant hormones (“phytohormones”) in the weed <em>Arabidopsis thaliana</em>. Specifically, she employs high- throughput sequencing to examine the myriad transcripts, or protein- making instructions, produced when the phytohormone abscisic acid (ABA) begins cascades of chemical chatter in response to an environmental stressor, such as drought.</p><p><a href="http://inside.salk.edu/">Click here</a> to view the most recent issue of Inside Salk.</p><p><strong>About the Salk Institute for Biological Studies:</strong></p><p>Every cure has a starting point. The Salk Institute embodies Jonas Salk’s mission to dare to make dreams into reality. Its internationally renowned and award-winning scientists explore the very foundations of life, seeking new understandings in neuroscience, genetics, immunology, plant biology and more. The Institute is an independent nonprofit organization and architectural landmark: small by choice, intimate by nature and fearless in the face of any challenge. Be it cancer or Alzheimer’s, aging or diabetes, Salk is where cures begin.</p><iframe src="https://cdn.embedly.com/widgets/media.html?url=https%3A%2F%2Fpowered.by.rabbut.com%2Fp%2FcLiZ%3Fc%3D0&amp;src=https%3A%2F%2Fpowered.by.rabbut.com%2Fp%2FcLiZ%3Fc%3D0&amp;type=text%2Fhtml&amp;key=a19fcc184b9711e1b4764040d3dc5c07&amp;schema=rabbut" width="500" height="500" frameborder="0" scrolling="no"><a href="https://medium.com/media/b4fca03ef76f2f8979c8390ad8580f09/href">https://medium.com/media/b4fca03ef76f2f8979c8390ad8580f09/href</a></iframe><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=f119ea49f942" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[A Masterful Design]]></title>
            <link>https://medium.com/@salkinstitute/a-masterful-design-3d3b531cc85a?source=rss-25ad4702628b------2</link>
            <guid isPermaLink="false">https://medium.com/p/3d3b531cc85a</guid>
            <category><![CDATA[architecture]]></category>
            <dc:creator><![CDATA[Salk Institute]]></dc:creator>
            <pubDate>Fri, 12 May 2017 21:04:02 GMT</pubDate>
            <atom:updated>2017-05-12T21:04:02.100Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*IKz6rRMB7kwqbkbNhAEo-g.jpeg" /><figcaption>Salk Institute courtyard</figcaption></figure><h4>Updates to the Salk Institute’s iconic architecture ensure that great science and the original vision of the design live on.</h4><p>Most people don’t associate concrete with beauty. But for Jonas Salk, founder of the Salk Institute, and Louis Kahn, famed architect who designed the building, selecting the right concrete for what would become a historical icon deserved special attention.</p><p>“Concrete is the material of parking garages and overpasses and highways, but in the Salk Institute, the concrete has an enormous warmth to it and changes in beautiful ways as the sun moves around or the fog rolls in,” says Nathaniel Kahn, son of Louis Kahn and creator of the Oscar-nominated 2003 documentary <em>My Architect</em>. He recalls his father examining the sand that would go into the concrete under a microscope, as he looked for the perfect hue. “It couldn’t be too green or too blue, like most concrete. It had to have warmth.”</p><p>The team mulled over many samples to find the perfect fit. Kahn ended up drawing inspiration from Roman times to select “pozzolanic” concrete, which turns a subtle pink when the sunlight hits. Once the concrete was set in the building, completed in 1965, Kahn allowed no further processing of the finish — no grinding, no filling, and above all, no painting. As a result, the building’s exterior today looks much as it did back then. The lack of a finish is intentional: in some ways the look of the unfinished materials is a reflection of the fundamental, bare-bones biology the scientists within strive to uncover, day in and day out, to better understand disease and development.</p><p>“As a teenager, I saw the building as stark and sterile, but as I grew to adulthood I came to see the spiritual quality of the building and realized what an architectural masterpiece this is,” says Jonathan Salk, youngest of Jonas Salk’s three sons. “My father loved this building. He had a way of walking along and absent-mindedly touching the surface of the concrete to connect with it as if it were a friend or family member.”</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*NYZ5oN6PNpCFyFYhXlTOkg.jpeg" /><figcaption>Construction complete: July 1965</figcaption></figure><p>When visiting the Salk Institute for the first time, one may not notice the subtle selection of the concrete, like many other careful touches that help make the building the historical structure it is today. Visitors walk past the two east buildings (a later addendum to the design to support the Institute’s growing administrative and technology needs) beneath towering eucalyptus trees, up a few steps bordered by a modest orange grove to finally reach the travertine courtyard, where they pause at the grand view. Flanked on either side by identical buildings, the courtyard overlooks the wild Southern California bluffs and directs the visitor’s gaze to the infinite expanse beyond the Pacific. A slender murmuring stream dubbed the “River of Life” cuts along the travertine to point to the sea, and lines up directly with the sunset during the spring and fall equinoxes.</p><p>“You walk up several steps and suddenly you’re in this courtyard, the sea is beyond, the continent behind you, the sun is shining, maybe a gull is circling. You somehow connect with what it is to be a human being and you feel your own potential,” says Nathaniel Kahn. “Art does that.”</p><p>The Institute is still considered one of Louis Kahn’s greatest masterpieces and has been described as a temple to nature and a monument to scientific thought. And, perhaps most astonishingly, the Institute has held up over the decades, its prescient design able to adapt to the rapidly changing technological demands of modern science, ensuring the Institute is a place where world-renowned discoveries continue to happen. Now, thanks to the recent completion of a Getty Institute-guided conservation management plan and teak restoration project, the Salk Institute will continue to enjoy many more years of housing breakthroughs in science.</p><h3>Built for tomorrow</h3><p>The level of care and commitment that two of the time’s most visionary artistic and scientific minds — Kahn and Salk — put into the building saved it from the obsolescence that many other great buildings suffer and created the sustainable, functional site that is still the Salk Institute today. Clever practical design features complement an ethos of simplicity and inspiration. As Salk famously said, the building “guesses tomorrow.”</p><p>“There is no other place like the Salk Institute,” says the Institute’s President, <a href="http://www.salk.edu/scientist/elizabeth-blackburn/">Elizabeth Blackburn</a>. “Here, one has the mental and physical space to think deeply and collaborate to unravel the complexities of biology and achieve great work.”</p><p>One stroke of architectural genius that allows for the Institute’s remarkable flexibility was the physical design of the floors. Kahn separated floors that contained lab spaces and offices from ones that contained electricity, ventilation and other utilities. These interstitial spaces allow maintenance and other work to go on without interrupting science. On the alternating three floors that conduct science (lower, ground and upper), massive 245-foot-long spaces supported by beams at the perimeters permit labs to be even more configurable. Removable walls and windows can be adjusted over time as new scientists and technologies come in.</p><p>This open floor plan, aside from being adaptable, also prompts a deliberately collaborative environment. No borders separate individual labs in order to encourage scientists to share equipment and bump into each other, perpetually cross-pollinating ideas from different fields of biological research and occasionally leading to collaborative, world-changing discoveries. Nowadays the concept of a collaborative workspace is all the rage, but in the ’60s, not many buildings were designed with open, flowing spaces to prompt the open exchange of ideas. But the Institute has a balance: scientists can also retreat into office spaces or studies when they need solitude or time to reflect.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/600/1*9rbp-vPdwPwt9SXasl_sGw.jpeg" /><figcaption>The “River of Life” cuts through the travertine courtyard and points to the Pacific Ocean.</figcaption></figure><p>The single courtyard was also designed with collaboration and unity in mind, to prompt happenstance encounters. Initially, the central plaza — the most memorable feature of the Institute — was conceived as two, but the design didn’t sit well with Salk, who realized it might create a divide and result in two cultures at the Institute rather than one. In a famous moment in architecture, he and Kahn told the team they had to start again, that it was worth it to get it right. They redesigned it with a single central space, which Kahn debated making into a monastic garden or covering with trees. But when Mexican modern architect Luis Barragán visited, he reportedly told Kahn that the space should be an open plaza, without vegetation so it could function as a civic space, resulting in the dramatic, single travertine plaza that mirrors the openness of the sky today.</p><p>Keeping to the sense of staying in touch with nature and science, placement of many of the Institute’s studies, stairwells and restrooms was designed to require people to step outside, forcing a break from the inside and yielding a quiet moment to appreciate nature, fresh air, sunshine or a sea breeze. The thoughtfulness toward nature continues with sustainability crafted into the building’s design. For one, Kahn added light wells — long open spaces — to let light pour into the floors below ground level to reduce the need for manmade illumination. For another, the “River of Life” and fountain at its end capture rain runoff in an underground cistern, which is used to replenish the water feature. Additionally, in the 1990s, an expanse of solar panels was added, generating a half megawatt of power that provides the air conditioning for the entire Institute. “It’s amazing that this building, designed over 50 years ago, still functions as a cutting-edge research institute today,” says <a href="http://www.salk.edu/scientist/thomas-albright/">Thomas Albright</a>, a Salk neuroscientist and head of the Vision Laboratory who studies not only vision but also the connections between the brain and architecture. “Aside from being an inspiring structure, that continued functionality speaks to the design’s original intent of paying homage to science and art.”</p><p>Indeed, the building still provides inspiration today for many architects and artists, and was the subject of a Robert Redford documentary on the “souls” of buildings, called <em>Cathedrals of Culture</em>.</p><h3>Conserving for the future</h3><p>Even the most well designed buildings experience some wear and tear. The Salk’s 50th anniversary in 2015 also marked the age when most Modernist buildings, bare of the facades and finishes that provide other structures some buffer against time, need restoration.</p><p>For Kahn’s iconic structure, the teak wood covering the window systems and other exterior openings were the first call for preservation. The warm reddish wood panels mark a professor’s study, and are meant to balance out the concrete with organic tones. Kahn had also chosen an unfinished look for the teak surrounding the study towers and west office windows, and he directed that no sealer or stain be applied to the wood. However, Kahn could not have predicted that the Institute’s signature panels would weather from exposure to the marine environment as well as to a fungal infection from nearby eucalyptus trees that resulted in a black patina on the lighter wood.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/960/1*ZzgG2tHjYI11MWNFcBrmyA.jpeg" /><figcaption>Museum of Art debuts Kahn collection — <em>Louis Kahn: The Power of Architecture</em>, featured last winter at the San Diego Museum of Art, paid tribute to one of the most influential architects of the 20th century. The retrospective exhibition presented over 200 objects related to his selected buildings and projects in the form of architectural models, plans, original drawings, photographs, films and more.</figcaption></figure><p>To restore one of the Institute’s key features — the teak window wall assemblies — the Salk Institute partnered with <a href="http://www.getty.edu/conservation/">The Getty Conservation Institute</a> (GCI) under its Conserving Modern Architecture Initiative to develop a preservation strategy. GCI conducted historical research, on-site condition surveys, physical and laboratory analysis of the teak, surface coatings and fungus, and a series of mock-ups trialing conservation solutions in order to develop a conservation program. A conservation management plan for the long-term care of the overall site was recently completed with support from the <a href="http://www.getty.edu/foundation/">Getty Foundation</a> as part of its Keeping It Modern Initiative.</p><p>According to Getty Conservation Institute project specialist Sara Lardinois, “The GCI sought to address issues on a long- term basis while preserving cultural significance and addressing the needs of those managing the site. Our aim was to help the Salk Institute incorporate a conservation approach into its overall site management at a critical point in the building’s history — the 50-year mark often coincides with the need for a first major repair in modern buildings.”</p><p>To be good environmental stewards, GCI and Salk took a scientific, almost surgical approach to the repair and conducted forensics on the wood, according to Tim Ball, Salk’s senior director of Facility Services. A feasibility study helped them understand how to preserve and repair what was already on the building in order to use as much existing wood as possible.</p><p>After three years of study and research, GCI provided a guide for restoration, which, under the execution of the architecture firm Wiss, Janney, Elstner Associates, Inc., and construction firm Rudolph and Sletten, began in 2016 and will end in the summer of 2017. Through this careful planning, the effort was able to reuse over 70 percent of the original teak, a figure that Ball says is a remarkable success.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/767/0*cNlbqGbIxv6WiAP_.jpg" /><figcaption>The Getty Conservation Institute developed a preservation strategy to replace and restore damaged teak in the window wall assemblies.</figcaption></figure><p>“We got at least a minimum of 50–70 years more on the old wood thanks to the conservation plan,” says Ball. The treatment included UV protection, resin and biocide on the teak to reject biospores and help the teak age uniformly. They also created a weather barrier system to prolong the life of the teak. The next steps are restoring some of the concrete as well as the travertine courtyard.</p><p>“When we talk about preserving a place, it’s not just the physical environment we’re preserving, we’re preserving the idea of a place and the possibilities that will come out of the place,” adds Nathaniel Kahn. “Through preservation efforts such as this, ideas that will transform our civilization and make it great can continue to come from places like the Salk Institute.”</p><p><a href="http://inside.salk.edu/">Click here</a> to view the most recent issue of Inside Salk.</p><p><strong>About the Salk Institute for Biological Studies:</strong></p><p>Every cure has a starting point. The Salk Institute embodies Jonas Salk’s mission to dare to make dreams into reality. Its internationally renowned and award-winning scientists explore the very foundations of life, seeking new understandings in neuroscience, genetics, immunology, plant biology and more. The Institute is an independent nonprofit organization and architectural landmark: small by choice, intimate by nature and fearless in the face of any challenge. Be it cancer or Alzheimer’s, aging or diabetes, Salk is where cures begin.</p><iframe src="https://cdn.embedly.com/widgets/media.html?url=https%3A%2F%2Fpowered.by.rabbut.com%2Fp%2FcLiZ%3Fc%3D0&amp;src=https%3A%2F%2Fpowered.by.rabbut.com%2Fp%2FcLiZ%3Fc%3D0&amp;type=text%2Fhtml&amp;key=a19fcc184b9711e1b4764040d3dc5c07&amp;schema=rabbut" width="500" height="500" frameborder="0" scrolling="no"><a href="https://medium.com/media/b4fca03ef76f2f8979c8390ad8580f09/href">https://medium.com/media/b4fca03ef76f2f8979c8390ad8580f09/href</a></iframe><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=3d3b531cc85a" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[SURVIVING SUPERBUGS]]></title>
            <link>https://medium.com/@salkinstitute/surviving-superbugs-3ba04c9a2a5?source=rss-25ad4702628b------2</link>
            <guid isPermaLink="false">https://medium.com/p/3ba04c9a2a5</guid>
            <category><![CDATA[microbiome]]></category>
            <category><![CDATA[infectious-disease]]></category>
            <category><![CDATA[microbiology]]></category>
            <category><![CDATA[antibiotics]]></category>
            <category><![CDATA[health]]></category>
            <dc:creator><![CDATA[Salk Institute]]></dc:creator>
            <pubDate>Mon, 08 May 2017 23:35:02 GMT</pubDate>
            <atom:updated>2017-05-08T23:35:02.713Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*J-BNKnYea8BSE6jfiwd2Dg.jpeg" /><figcaption>Image credit: Salk Institute/Waitt Center</figcaption></figure><h4>ENDING THE ARMS RACE WITH INFECTIOUS DISEASE</h4><p>Two years ago, <a href="http://www.salk.edu/scientist/janelle-ayres/">Janelle Ayres</a> received a frantic text from her mother 12 hours after her father was discharged from the hospital.</p><p>“He can’t walk. I need to call an ambulance. I don’t know what’s wrong with him.”</p><p>Ayres’ father, Robert Lamberton, had undergone routine gallbladder surgery and was supposed to be recovering at her parents’ home on the outskirts of Oakland. It was a common surgery and nothing was supposed to go wrong. But something was very wrong. Ayres knew from the symptoms her sister described on the phone that her father had sepsis, a poorly understood condition in which the body’s reaction to an infection is more deadly than the infection itself.</p><p>She caught the first flight from San Diego to Oakland and rushed to the hospital where her father had been taken by ambulance. When she entered his room in the intensive care unit, her father smiled and gave her the thumbs up she’d seen a thousand times as a child.</p><p>The doctors explained that the gallstones went undetected for too long, resulting in an infection in his gallbladder. The bacteria had spread to his bloodstream and taken hold in his spine. They confirmed he had sepsis. The only treatment option was administration of broad-spectrum antibiotics.</p><p>Over the next several days, Ayres stayed in the hospital room with her father, obsessively watching his vital monitors. She was hoping the next blood pressure read would be higher or the next ventilator read would be lower, anything to suggest the antibiotics were working. All the while, her father watched endless reruns of Blue Bloods, a cop drama that he didn’t particularly like, but it was something to do. His numbers never got better, and as the days progressed, his conditioned worsened. The infection was antibiotic resistant, making the only treatment option available to him useless.</p><p>Her father fought for nine days after he was readmitted to the hospital. But in the end, the bacteria won.</p><blockquote>Each year*:</blockquote><blockquote>· 700,000 people die from antimicrobial-resistant infections worldwide.</blockquote><blockquote>· 23,000 people die from antibiotic-resistant infections in the United States.</blockquote><blockquote>· 2 million people are infected by antibiotic-resistant bacteria in the United States.</blockquote><blockquote>*Source: CDC and WHO</blockquote><h3>From fighting to surviving</h3><p>Losing a parent is emotionally devastating, but for Ayres the ordeal also was surreal and frustrating. Surreal because Ayres, an associate professor at the Salk Institute and one of the world’s foremost experts on bacterial infections, watched a loved one succumb to the kind of infection she studies every day in the laboratory. Frustrating because in her research she had discovered a completely different approach to treating infections — an approach that likely would have saved his life.</p><p>Her first breakthrough had come seven years earlier, when she was a graduate student at Stanford University School of Medicine. She earned her admission to graduate school and a prestigious research fellowship to fund her education through hard work — the only kind her father believed in. A German immigrant, after his service in the Navy and Vietnam, Lamberton went to aviation school and became a jet engine mechanic for National Airmotive Corporation and later Rolls Royce, both in Oakland. He had commuted more than two hours each day for his job and for as long as Ayres can remember, he worked seven days a week. He rarely took a sick day, and he raised his three daughters with that same work ethic. He pushed them to set goals and taught them that if they worked hard they could accomplish anything. He insisted that his daughters take after school jobs in high school so that they could learn the value of hard work and accountability. During high school Ayres served ice cream at Baskin-Robbins and worked at a grocery store. During her undergraduate years at the University of California, Berkeley, similar to her father, she commuted over two hours each day and she worked full time in a molecular cytogenetics laboratory at Lawrence Livermore National Laboratory. The schedule was demanding and tiring, but she graduated with her bachelor’s degree and a 4.0 grade point average — a goal she had set when she started college.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*fetNt9CU6iajvQQ84arUWQ.jpeg" /><figcaption>Janelle Ayres, Associate Professor, Nomis Foundation Laboratories for Immunobiology and Microbial Pathogenesis, Helen McLoraine Developmental Chair</figcaption></figure><p>While at Berkeley, Ayres attended a seminar on infectious diseases that inspired her to devote her career to combating the global health crisis of infectious diseases and drug resistance. To pursue her goal, she entered the microbiology and immunology doctorate program at Stanford University, working with David Schneider, a world-renowned immunologist and infectious disease researcher. As part of her research in Schneider’s lab, Ayres studied how fruit flies respond to bacterial infections, searching for clues in the flies’ DNA to the biological interactions between a host and pathogen. In a breakthrough experiment, Ayres dosed a group of flies with <em>Listeria</em> bacteria, a food-borne microbe that causes a potentially deadly infection in humans known as listeriosis. She found that some of the infected flies were more resilient than others, showing fewer symptoms of disease and better chances of survival. What was surprising was that the flies’ chances were unrelated to the level of infection in their bodies. Of two flies with the same degree of infection, one might die while the other survived. It might not sound like a dramatic result, but it challenged one of the pillars of immunology dogma: that survival during an infection depends entirely on how effective the immune system is at killing the offending pathogen. Ayres’ experiments showed that flies with similar immune responses had very different outcomes. She realized that something other than the immune system was kicking in during the infections, something that focused not on killing an invading pathogen but on saving the host’s life. She gave this phenomenon a name: tolerance defense system. The implications were profound and heretical.</p><p>Since the dawn of the field of immunology, the reigning mantra has been that the best defense is a good offense. The predominant metaphor has been war and the goal was the eradication of the pathogen — the enemy. It served humanity well — for a while. The first effective way of dealing with pathogens was soap, a low-tech (and still very effective) tool for killing microbes. Nowadays, we expect doctors and nurses to wash their hands, but the modern concept of medical hygiene didn’t really exist until the mid-1800s, when an Austrian obstetrician named Ignaz Semmelweis began advocating for doctors to scrub before delivering babies. As a result, far fewer women died from infections contracted during childbirth. Later, in the early 1900s, the German scientist Paul Ehrlich popularized the idea of a “magic bullet” drug that would target a specific bacterial infection but not harm patients. The first such drug was discovered in 1928 by Scottish scientist Alexander Fleming, who found penicillin in a moldy laboratory dish. Since then, more than a hundred antibiotics have been developed and those drugs have saved hundreds of millions of lives. The early generation antibiotics were so effective that many health officials declared infectious diseases would soon become a worry of the past.</p><p>But the enemy is wily. Over time bacteria evolve resistance to drugs, an ability largely overlooked in the early exuberance for magic bullets. Overuse and misuse of antibiotics have created a global health crisis. Every year in the United States alone, 2 million people are infected by antibiotic-resistant bacteria. Of those, at least 23,000 die from the infections. Worldwide, approximately 700,000 people succumb every year to antimicrobial-resistant infections. As tragic stories and urgent warnings spread, superbugs can seem like fearsome monsters sprung from out of nowhere, but in truth they are of humanity’s own making. And fearsome as they are, we keep feeding them. Every year, the problem gets worse, driven by overuse of antibiotics in humans and livestock that puts intense evolutionary pressure on bacteria to develop resistance to the drugs. As a result, the more we use antibiotics, the less useful they are.</p><p>Highlighting the urgency of the situation, the World Health Organization (WHO) recently published medicine’s equivalent of the FBI’s Most Wanted List, naming a dozen superbugs that pose the greatest threat to human health. At the top of the list are microbes that present a particular risk in hospitals, including <em>Acinetobacter, Pseudomonas</em> and various bacteria that live in the gut, such as <em>Klebsiella</em>, <em>Serratia</em>, <em>Proteus</em> and <em>E. coli</em>, the type that took Robert Lamberton’s life. The WHO announcement warned of the decline in the development of new antibiotics. Compared to other classes of drugs, antibiotics are far less profitable for drug makers because they are only used for short periods of time — during an infection — and their clinical effectiveness ends when bacteria evolve resistance. Many pharmaceutical companies have moved away from antibiotic research in favor of more profitable drugs used for chronic illnesses, such as antidepressants, targeted cancer therapies, anti-inflammatories and drugs for high blood pressure and cholesterol. Ironically, in many cases, patients suffering from these chronic diseases have weakened immune systems and part of their treatment regimen is antibiotics. In releasing their list, the WHO officials were sounding an alarm that humanity is approaching a dangerous superbug-filled chasm at a time when the pipeline for new antibiotics is running dry. The war cry is clear: We need more weapons! And yet, from Ayres’ perspective, this “arms race” mentality has limits that have been laid bare by history and the superbug epidemic. The current crisis has its roots in the early days of infectious disease medicine and its myopic focus on fighting with microbes. Her research points to another way of thinking about disease — one that focuses less on killing bacteria and more on helping patients survive. It offers the potential to develop drugs that promote survival of patients without driving drug resistance in pathogens.</p><h3>From Typhoid Mary to tolerance</h3><p><a href="http://www.salk.edu/news-release/feed-cold-starve-fever-not-fast-according-salk-research/">Ayres’ team discovered that this strain of E. coli bacteria (shown growing in a lab dish) helped mice tolerate dangerous infections.</a>When Ayres joined the Salk Institute in 2013, she was intent on finding out more about the mysterious survival skills she’d discovered in fruit flies while at Stanford. She built her Salk laboratory to focus on exploring the same phenomena in mice, fellow mammals that offer more insight into human infectious disease biology. Repeating her fruit fly experiments in mice, she found that rodents appear to have a similar tolerance defense system in place. By extension, we humans very likely have such a system at work in our bodies. And, in fact, evidence for this comes from the examination of a variety of human infectious disease cases. Take Mary Mallon, an Irish immigrant to the United States in 1883, known to history by the infamous moniker a prominent medical journal gave her: Typhoid Mary.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/300/1*Gvf2wvsETwv5u-0QEILI3g.jpeg" /><figcaption>Ayres’ team discovered that this strain of E. coli bacteria (shown growing in a lab dish) helped mice tolerate dangerous infections.</figcaption></figure><p>Mallon was a cook who worked for several families and public kitchens in New York in the early 1900s. She also was an asymptomatic carrier of <em>Salmonella</em> Typhi, the bacterium that causes typhoid fever. She showed no symptoms of the disease, yet was a “super shedder” who left a trail of typhoid outbreaks and deaths as she moved from kitchen to kitchen. Mallon was convinced she was being unfairly persecuted when health officials asked her to stop cooking — she even refused their pleas to at least wash her hands before handling food. Exasperated, authorities arrested and quarantined her for three years, releasing her only after she promised not to work as a cook. She stuck to the bargain for a while, but then changed her name to Mary Brown and went back to concocting her deadly dishes. Eventually, as a public safety measure, she was found and forcibly quarantined on a small island in New York’s East River for the remainder of her life. Estimates hold that prior to her incarceration, at least 50 people were infected and three people died from eating her tainted fare. Like Ayres’ infection-tolerant flies, Mallon and other asymptomatic carriers of infections provide evidence that our bodily relationship to microbes is not as simple as kill-or-be-killed. Mallon breezed along with trillions of <em>S</em>. Typhi in her body while some of her customers dropped like flies. Another clue that our relationship with bacteria isn’t solely adversarial is our microbiome, the community of beneficial bacteria living in and on our bodies, mostly in our intestinal tract. Our bodies contain more than 9 trillion bacteria, about 10 times as many bacteria as human cells, and this community of microbes collectively weighs about 3 pounds — as heavy as our brain. There is much evidence that we have coevolved a symbiotic relationship with our microbial passengers. Among other things, they make enzymes essential for helping us digest food, they generate molecules that help our cells function correctly and they are essential for maturation of our immune system.</p><p>Ayres suspected this relationship goes much further and that our microbiome might play a central role in the tolerance defense system she discovered. If the microbiome was in fact key to infection tolerance, she hypothesized, the composition of a person’s microbiome would help determine their ability to tolerate an infection. To test this, she collected mice from labs around the country. The mice were genetically identical, but carried microbiome communities specific to their geographic origins. A mouse from Long Island, New York, had a different array of bacteria, for instance, than one from Northern California. In her Salk laboratory, Ayres and her team studied how mice from different locations responded to intestinal infections of <em>Salmonella</em> Typhimurium (a relative of <em>Salmonella</em> Typhi) and pneumonia caused by the bacteria <em>Burkholderiathailandensis</em>. They discovered that one population of mice showed no signs of muscle wasting, one of the most dangerous symptoms of serious infections. These resilient mice didn’t have a genetic advantage — all the populations were genetically identical — nor did they have stronger immune systems. All signs were pointing to a superior tolerance defense system. By comparing the makeup of the intestinal microbiome of the different populations of mice, Ayres’ team identified a strain of <em>E. coli</em> that was present only in the more resilient mice. But was this strain of <em>E. coli</em> really the superhero bug in the story? To test this, they gave mice lacking the strain an oral treatment of the beneficial <em>E. coli</em> and observed what happened when they were sick. Sure enough, the mice gained the ability to maintain their muscle and fat mass during infections.</p><p>This was the first direct evidence that a specific bacteria from the microbiome could help an organism endure a pathogen by promoting the tolerance defense system. Ayres and her team pushed on in their experiments and found that in response to the infection, the <em>E. coli</em> was leaving the gut and moving into the animal’s fat deposits. There it was activating metabolic switches that communicated with the muscles, nourishing them to prevent wasting. Not only was a bacterium maneuvering in the body to bolster its defenses, it was activating genetic pathways that might well be part of the tolerance defense system. The implications were profound.</p><p>The discovery demonstrated the possibility of entirely new classes of therapies. Superhero bacteria such as Ayres’ <em>E. coli</em> might be used as therapies to help patients tolerate infections — microbes as medicine. New types of drugs could focus on promoting a patient’s health, raising their chances of surviving infections. Unlike antibiotics, such drugs wouldn’t target pathogens and so wouldn’t drive the evolution of drug resistance. This could spell the end of our arms race with pathogens. Tolerance- enhancing drugs could be used for treating other diseases such as cancers and inflammatory conditions that cause similar pathologies in the body as infectious diseases. Muscle wasting, for example, also occurs in response to tumors and chemotherapy. In that vein, Ayres and her team showed that their tolerance-promoting E. coli can block muscle wasting caused by inflammatory bowel disease. They are now testing this approach in preclinical cancer models to determine the spectrum of diseases in which this beneficial microbe can promote tolerance.</p><p>Ayres’ research offers a ray of hope that is desperately needed. The 20th century, thanks to rapid advances in medical hygiene, vaccinations and antibiotics, was marked by a seemingly inexorable march of progress in the fight against infectious disease. In the 21st century, the battle has tilted against us. Our medical advances have created monsters that grow more lethal the more we fight them.</p><p>Ayres decided to take on infectious diseases years before her father’s death. But now it’s personal. “When I talk about infections, my dad is now the patient I am talking about,” she says. “I didn’t care whether the antibiotics were killing the bacteria, I care that they did nothing to help my father survive. It shouldn’t have happened to him and I don’t want it to happen to anyone else.”</p><iframe src="https://cdn.embedly.com/widgets/media.html?url=https%3A%2F%2Fpowered.by.rabbut.com%2Fp%2FcLiZ%3Fc%3D0&amp;src=https%3A%2F%2Fpowered.by.rabbut.com%2Fp%2FcLiZ%3Fc%3D0&amp;type=text%2Fhtml&amp;key=a19fcc184b9711e1b4764040d3dc5c07&amp;schema=rabbut" width="500" height="500" frameborder="0" scrolling="no"><a href="https://medium.com/media/b4fca03ef76f2f8979c8390ad8580f09/href">https://medium.com/media/b4fca03ef76f2f8979c8390ad8580f09/href</a></iframe><h3>THE SALK INSTITUTE FOR BIOLOGICAL STUDIES:</h3><p>Every cure has a starting point. The Salk Institute embodies Jonas Salk’s mission to dare to make dreams into reality. Its internationally renowned and award-winning scientists explore the very foundations of life, seeking new understandings in neuroscience, genetics, immunology, plant biology and more. The Institute is an independent nonprofit organization and architectural landmark: small by choice, intimate by nature and fearless in the face of any challenge. Be it cancer or Alzheimer’s, aging or diabetes, Salk is where cures begin.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=3ba04c9a2a5" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Visualizing Nature Inside the Lab and Out]]></title>
            <link>https://medium.com/@salkinstitute/visualizing-nature-inside-the-lab-and-out-f911ea18c3ee?source=rss-25ad4702628b------2</link>
            <guid isPermaLink="false">https://medium.com/p/f911ea18c3ee</guid>
            <category><![CDATA[health]]></category>
            <category><![CDATA[biology]]></category>
            <category><![CDATA[diabetes]]></category>
            <category><![CDATA[science]]></category>
            <category><![CDATA[health-technology]]></category>
            <dc:creator><![CDATA[Salk Institute]]></dc:creator>
            <pubDate>Fri, 10 Jun 2016 17:54:16 GMT</pubDate>
            <atom:updated>2016-06-10T17:54:16.175Z</atom:updated>
            <content:encoded><![CDATA[<p>Zachary Katz is a visual person: from insect-devouring plants to bustling cells, he strives to see what happens in nature. While growing up in Arizona and then Florida, Katz and his brother gathered specimens of rocks and plants (particularly of the carnivorous variety). Katz took up photography to catalog his collections, leading to his interest in another method for visualizing the natural world, microscopy.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*amTK_Fr0uXTr7xSCV3QR3A.jpeg" /><figcaption>Zachary Katz</figcaption></figure><p>Working in <a href="http://www.salk.edu/scientist/bjorn-lillemeier/">Björn Lillemeier’s lab</a> at Salk, Katz creates new kinds of microscopes to observe single immune cells, the body’s first responders to threats. Immune system sentries called T cells rapidly summon a swarm of defensive cells when they detect intruders. But when T cells aren’t operating correctly, they can mistakenly ignore deadly threats (like cancer) or attack the body and cause autoimmune or immune-deficiency disorders, such as allergies and <a href="http://www.salk.edu/science/research/metabolism-and-diabetes/">type 1 diabetes</a>.</p><iframe src="https://cdn.embedly.com/widgets/media.html?src=https%3A%2F%2Fwww.youtube.com%2Fembed%2Fr8uC1aucNC8%3Ffeature%3Doembed&amp;url=http%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3Dr8uC1aucNC8&amp;image=https%3A%2F%2Fi.ytimg.com%2Fvi%2Fr8uC1aucNC8%2Fhqdefault.jpg&amp;key=d04bfffea46d4aeda930ec88cc64b87c&amp;type=text%2Fhtml&amp;schema=youtube" width="854" height="480" frameborder="0" scrolling="no"><a href="https://medium.com/media/afccff4a127b2bfa94e926d80452a630/href">https://medium.com/media/afccff4a127b2bfa94e926d80452a630/href</a></iframe><p>T cells malfunction when proteins on their outside membrane confuse safe cells with sick ones. By building tools to observe which — and where — molecules are interacting with those membrane proteins, Katz can find ways to control T cells. To catch the motion of these fleeting interactions, Katz programs strobe lasers to light up molecular interactions in pulses without bleaching them. Charting never-before-seen interactions on the T cell’s surface is the first step in designing small molecules that can turn on or off T cells at will, providing a new defense against a host of diseases.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/800/1*4NkRjeIvM0ZDrEApZmvJ-A.jpeg" /></figure><p><em>The </em><a href="http://www.salk.edu/"><em>Salk Institute</em></a><em> embodies Jonas Salk’s mission to dare to make dreams into reality. We explore the very foundations of life, seeking new realities in neuroscience, genetics, immunology and more. We are small by choice, intimate by nature, fearless in the face of any challenge. We live to discover. Be it cancer or Alzheimer’s, aging or diabetes, we understand that every cure has a starting point. Salk is where cures begin.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=f911ea18c3ee" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[An Interview with Salk Institute President Elizabeth Blackburn]]></title>
            <link>https://medium.com/@salkinstitute/an-interview-with-salk-institute-president-elizabeth-blackburn-684dc03b2f35?source=rss-25ad4702628b------2</link>
            <guid isPermaLink="false">https://medium.com/p/684dc03b2f35</guid>
            <category><![CDATA[biology]]></category>
            <category><![CDATA[cancer-biology]]></category>
            <category><![CDATA[science]]></category>
            <dc:creator><![CDATA[Salk Institute]]></dc:creator>
            <pubDate>Tue, 17 May 2016 21:55:47 GMT</pubDate>
            <atom:updated>2016-05-17T21:55:47.280Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/999/1*FrH8XJZN1okiCnf2Qgo7aA.jpeg" /><figcaption>Elizabeth Blackburn</figcaption></figure><h3>When Jonas Salk announced the discovery of the polio vaccine in 1955, Elizabeth Blackburn was six years old and busy collecting tadpoles and ants a world away in her native Tasmania. She couldn’t have known it then, but science, discovery and Jonas Salk would all play important roles in her future.</h3><p>After his vaccine discovery, Salk went on to found the <a href="http://www.salk.edu/">Salk Institute for Biological Studies </a>and Blackburn went on to a distinguished career as a pioneering molecular biologist whose research would eventually earn her a Nobel Prize.</p><p>This January, Blackburn began serving as the new president of the Salk Institute, taking the helm of Jonas Salk’s world-renowned scientific enterprise and leading an elite cadre of scientists as they push the frontiers of discovery in fields such as <a href="http://www.salk.edu/science/research/cancer-biology/">cancer</a>, <a href="http://www.salk.edu/science/research/neuroscience-and-neurological-disorders/">neuroscience</a>, <a href="http://www.salk.edu/science/research/aging-and-regenerative-medicine/">aging</a> and <a href="http://www.salk.edu/science/research/plant-biology/">plant biology</a>.</p><p>“Few scientists garner the kind of admiration and respect that Dr. Blackburn receives from her peers for her scientific accomplishments and her leadership, service and integrity,” says Irwin M. Jacobs, chairman of Salk’s Board of Trustees. “Her deep insight as a scientist, her vision as a leader and her warm personality will prove invaluable as she guides the Salk Institute on its continuing journey of discovery.”</p><p><a href="http://inside.salk.edu/"><em>Inside Salk</em></a><em> </em>magazine<em> </em>sat down for a conversation with Blackburn as she settled into her new office overlooking the coast of La Jolla.</p><h3>Did you ever consider a career outside of science?</h3><p>When I was a teenager, I had classic music lessons all through school. I really loved music and I played competently. I thought, ‘Wouldn’t it really be great to be someone whose life is really all about music?’ But another part of me was very realistic. Being competent at piano playing is a far cry from being a real performer and to love music isn’t to mean you can make a career out of it.</p><p>So I had the wistful dream of being a musician. But I also knew I loved science, even as a teenager. For over 50 years — most of my life! — I have been front and center a laboratory scientist. Science, to me, was the best thing that I could do. I do still noodle on the piano, mostly just for my own relaxation. We have a piano in our house in San Francisco, and my husband and son would make themselves scarce when I’d play. The only one who would put up with it was our parakeet, that had no means of escape and would chirp away merrily along with various sonatas and other piano pieces I play.</p><h3>Any other enduring passions besides science<br>and music?</h3><p>For years, I read every spy book and mystery book I could. More recently I’ve become fascinated by 20th century history, especially the earlier part of that century, when the world went through such major events and transitions. Now I’m really enjoying biographies, because people are so interesting. I’ve recently been reading a fascinating book called “Jonas Salk: A Life” by Charlotte DeCroes Jacobs. He was really an extraordinary person. The house we are renting here in La Jolla just happens to be next to his house, which is intriguing.</p><p>When I was young, I read a biography on <a href="https://en.wikipedia.org/wiki/Marie_Curie">Marie Curie</a> and that moved me very much, because I loved how she took on science. She had two kids whom she home schooled in physics. I loved the picture of this person who was so dedicated to science but was also a devoted mother. Her daughter who wrote the biography clearly adored her. That book really captivated my imagination about being a scientist.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*bCETSddJzSUOlk9l2BIPTQ.jpeg" /><figcaption>Salk Institute for Biological Studies, La Jolla, CA, USA</figcaption></figure><blockquote>Because it’s Salk! It’s such a special place. Your heart does a little leap every time you first step into the courtyard.</blockquote><h3>What made you decide to accept the position as president of Salk?</h3><p>Because it’s Salk! It’s such a special place. Your heart does a little leap every time you first step into the courtyard. The architecture is so extraordinary; it makes you wonder what it does for creativity. There has to be some amazing synergism that neuroscientists will have to figure out. There’s always been that special feeling about the place, and the science is really something special as well. So, when the possibility of becoming president came along, I got really excited. But then I told myself it would pass — but of course it didn’t. [Laughs] I really kept thinking about it, the next day and the next day, and I began to think, this could be real. A big part of my excitement was knowing the Institute as a non-resident fellow and having such an admiration for the scientists and their science that happens here and the ways it happens.</p><h3>Will you miss running a lab and being engaged in your own research?</h3><p>We have chapters in our lives. Even my scientific career went through many chapters. At different stages you could have called me a biochemist, a molecular biologist, a geneticist, a parasitologist, an RNA biologist, an enzymologist, somebody who works in cell biology, cancer and aging, and then a collaborator in clinical and human studies. All of those phases were different but always in some way focused on scientifically thinking about a central question: ‘How do these ends of chromosomes work?’ Which became: ‘How does it relate to human lives?’ I’ve really had my fun in the lab. Now the question is how to foster other people’s scientific careers. I’ve mentored graduate students and postdocs all throughout my career, but always as part of my own research program. As president of Salk, I now have the opportunity and the responsibility to pursue that mission at a larger scale and especially to grow younger people’s careers and success in science.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*z7sh-oH7Z5lx3qeuxgIpZA.jpeg" /><figcaption>Elizabeth Blackburn with Postdoctoral Researchers Laura Hale, Uri Magaram and Lourdes Tames</figcaption></figure><h3>Do people have misconceptions about science?</h3><p>There is a visual stereotype of the lone scientist wearing a white coat — and the coat hangs very straight indeed. It somehow suggests that the work is rigid, boring and solitary. In fact, science is probably one of the most social things on the planet. It’s all about ideas going viral among science communities. Scientists think deeply much of the time but if they don’t communicate what they did, in one sense it didn’t happen. If you’re doing a biological experiment and you don’t write down what you did in a notebook or publish it in a paper, that experiment never existed, right? If it never makes it out of your mind, it doesn’t advance science. So it’s an incredibly social and communal kind of enterprise. Science also has this interesting dynamic of balancing rigor with creativity. It’s a lot like art. You look at Picasso, and you think he’s creating very free-form simple-seeming works. But Picasso was taught early on how to draw in the most classic styles and he mastered those completely. His more creative work could launch from this rigorous training. The scientist’s lab coat is an emblem of the rigorous platform that launches the real creativity in science.</p><h3>The biological sciences have moved so rapidly in the past 60 years. What’s left to learn?</h3><p>I wonder in biology if we aren’t where physics was in the 19th century. We know so much about the molecules, cells and cellular signaling and other fundamentals about how things work at one level, and yet, at another level we don’t know a lot. We’re very mystified by the complexity of the whole organism. We look at all of the elements and say, ‘Gosh, how did this actually turn into a human who is functional for 70, 80, 90 or even 100 years?’ There was great confidence in 19th century physics, and a feeling that they had a handle on how things worked, but there were universes they hadn’t even dreamed of. We’re at this stage of justifiable pride in all we know about biology, and yet, we know it’s still very tough. In a hundred years, scientists may look back and say ‘They knew a lot of great rigorous biology, but boy, they were so naïve.’ We’ve already had a few surprises. For instance, how important RNA molecules are in many of the functions we thought proteins dominated. There are probably other worlds in biological systems that we’ve never imagined.</p><h3>How is technology changing biological sciences?</h3><p>Technology is letting us do remarkable things like study single cells and single molecules, and suddenly people are framing questions in ways that they never could before. There was no point in asking those questions in the past because there was no way to experimentally verify anything. Technologies are now revealing things that you couldn’t see before, and suddenly you can visualize what’s actually going on. This is opening up new understandings of biology — and therefore of disease. We can now ask questions about our biological complexity, about what makes things work so well, much better than would be expected. The more we understand these systems the better we will understand the diseases that disrupt them.</p><h3>As president of Salk, what are your aspirations for your time at the Institute?</h3><p>We can start with one very clear mission: to have great science thrive at Salk. So what does that mean? We’ll need funding, of course, that’s always critical, but money isn’t enough. You can have all the money in the world, but if you don’t have the right kind of environment that inspires people to do great science there’s no point. You have to always be asking what makes a scientific community greater than the sum of its parts. At Salk, everybody is committed to this idea that doing science — great science — is not only the most exciting thing they do but also that this is what will make a lasting impact on human wellbeing. The important thing is making sure that we have a community of people devoted and enabled to do that. It’s also important that people who train at Salk leave the Institute with not only the skill set to do rigorous, creative science, but with a passion to do really great science.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/436/1*3-PL8NtgIixjXnmqOxp_JA.jpeg" /></figure><p>Elizabeth Blackburn shared the Nobel Prize in Physiology or Medicine in 2009 for discovering the molecular nature of telomeres and for co-discovering telomerase, an enzyme that maintains telomere ends. The huge amount of the genetic material in the form of DNA in the cells of living organisms is physically compacted into miniscule bundles called chromosomes. Telomeres protect DNA by capping the ends of chromosomes and may act as sensors of aging as they shorten, marking a cell’s age and possibly changing its genetic programming over time. Telomeres have recently emerged as a unifying regulator and readout of human aging and may well be a major coordinator and link between various age-associated diseases.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=684dc03b2f35" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>